On July 28, CSPC PHARMA rose 3.86% in regular trading, trading at 8.46 HKD/share, with turnover of 22.63 million HKD. The rally was driven by multiple positive announcements released after market close on July 27.

The company issued a profit alert forecasting interim shareholder profit of RMB 5.9-6.2 billion for the first half, a significant increase from RMB 2.55 billion in the prior-year period. The growth was primarily attributed to a substantial rise in licensing fee revenue, with an USD 840 million upfront payment expected to be recognized in Q2. Subsidiary CSPC Innovation also expects H1 net profit of RMB 1.18-1.36 billion, successfully turning around from a prior-year loss.

Separately, the company announced that its Class 1 innovative drug HA1406 (amoxetine hydrochloride enteric-coated tablets) achieved its pre-specified primary efficacy endpoint in a Phase III clinical trial for depression treatment. The multicenter, randomized, double-blind, placebo- and active-controlled study demonstrated statistically significant results, with multiple secondary endpoints also showing favorable benefit trends, laying a data foundation for regulatory submission.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)